Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0002842
UniProt IDQ01130
Primary gene name(s)SRSF2
Synonym gene name(s)SFRS2
Protein nameSerine/arginine-rich splicing factor 2
Protein functionNecessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3', S=C or G or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. The phosphorylated form, by SRPK2 is required for cellular apoptosis in response to cisplatin treatment. {ECO:0000269|PubMed:19592491, ECO:0000269|PubMed:21157427}.
Subcellular locationNucleus {ECO:0000269|PubMed:21157427}. Nucleus, nucleoplasm {ECO:0000269|PubMed:21157427}. Nucleus speckle {ECO:0000269|PubMed:21157427}. Note=Phosphorylation by SRPK2 provokes its redistribution from the nuclear specke to nucleoplasm.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q01130
Gene Ontology
(Biological Process)
Complete annatation
mitotic nuclear division [GO:0007067];
mRNA 3'-end processing [GO:0031124];
mRNA export from nucleus [GO:0006406];
mRNA processing [GO:0006397];
mRNA splicing, via spliceosome [GO:0000398];
regulation of alternative mRNA splicing, via spliceosome [GO:0000381];
response to vitamin E [GO:0033197];
RNA export from nucleus [GO:0006405];
RNA splicing [GO:0008380];
termination of RNA polymerase II transcription [GO:0006369]
Gene Ontology
(Molecular Function)
Complete annatation
nucleotide binding [GO:0000166];
poly(A RNA binding [GO:0044822];
pre-mRNA binding [GO:0036002];
transcription corepressor activity [GO:0003714]
Gene Ontology
(Cellular Component)
Complete annatation
extracellular exosome [GO:0070062];
nuclear speck [GO:0016607];
nucleoplasm [GO:0005654];
nucleus [GO:0005634];
spliceosomal complex [GO:0005681]
Protein-protein interaction112325
Phylogenetic treeQ01130
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD31.090874345750380.0009749959545292120.0035547022318975
AZA vs. DISU-0.1620559613799760.5212934936022490.940509006088293
AZA vs. IL70.1788550046420390.3507374390743760.999311006273513
AZA vs. SAHA-0.3796305521386290.1195421798865220.440258690351681
DISU vs. CD3-1.266108705302040.0005667212149313980.00253870894320235
DISU vs. IL70.3319469218450390.1875163900024360.561354317911311
DISU vs. SAHA-0.2158582186961970.4596831383097290.798937533514497
DMSO vs. AZA0.03689375027244850.8249881772996051
DMSO vs. CD3-1.064765581165740.0009726450333008560.00334235798966182
DMSO vs. DISU0.1973802329032140.4179488762394810.875843663963036
DMSO vs. IL70.1492154986676510.4050814961164660.84722387968895
DMSO vs. SAHA-0.4229750195448930.07285144281734970.315229427131862
HIV vs. Mock in Activation0.06623797834777530.9151017177212170.999983755607037
HIV vs. Mock in Latency-0.03512993606902910.8308078561710790.999834320637052
IL7 vs. CD3-0.9048164036597660.005156058637780240.0171973229840485
SAHA vs. CD3-1.494570327060823.49338610963201e-050.000189712896115872
SAHA vs. IL7-0.5620123601313010.02115266887409350.104337477293222
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.507975 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.99 1.005 0.989 0.929 0.941
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
2KN4 NMR - A=9-101.
2LEA NMR - A=1-101.
2LEB NMR - A=1-101.
2LEC NMR - A=1-101.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat inhibited by 25416801
Rev inhibited by 11967326
Rev co-localizes with 7546906
HIV-1 virus replication enhanced by expression of human gene 18976975
Tat activated by 25889056
Tat interacts with 25496916

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa03040 Spliceosome - Homo sapiens (human)
hsa05168 Herpes simplex infection - Homo sapiens (human)